Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Montelukast use and the risk of neuropsychiatric adverse events in children
Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.
Umeå University, Faculty of Medicine, Department of Clinical Sciences, Child and Adolescent Psychiatry. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.ORCID iD: 0000-0003-0561-5998
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Sachs' Children and Youth Hospital, Stockholm, Sweden.
Show others and affiliations
2025 (English)In: JAMA pediatrics, ISSN 2168-6203, E-ISSN 2168-6211, Vol. 179, no 4, p. 418-427Article in journal (Refereed) Published
Abstract [en]

Importance: Spontaneous reports have indicated that montelukast increases the risk of neuropsychiatric adverse events, and the US Food and Drug Administration added a boxed warning about these risks in 2020. However, the potential mechanism is not well understood, and the observational evidence is scarce, particularly in children.

Objective: To assess the potential association between the use of montelukast and the risk of neuropsychiatric adverse events in children and adolescents.

Design, Setting, and Participants: This nationwide register-based cohort study used data from Sweden from January 1, 2007, to November 30, 2021. Participants included children aged 6 to 17 years who used montelukast and long-acting β-agonists (LABA). Data analysis was performed from December 2023 to April 2024.

Exposure: Montelukast vs LABA.

Main Outcomes and Measures: The primary outcome, any neuropsychiatric adverse event, was a composite of secondary outcomes, including anxiety; depression; sleep-related disorders; suicide and suicidal actions; disrupted control of activity, attention, and behavior; and confusion and psychotic-like symptoms. Outcomes were defined on the basis of diagnosis codes and dispensings of prescription drugs for specific neuropsychiatric symptoms. Patients were followed up from drug initiation to discontinuation, and treatment and censoring weights were used to adjust for potential confounding on baseline and selection bias from informative censoring. Pooled logistic regression was used to estimate hazard ratios (HRs).

Results: The final cohort included 74 291 children (mean [SD] age, 12.3 [3.3] years; 35446 female [47.7%]); 26462 used montelukast and 47829 used LABA. During a mean (SD) follow-up of 5.8 (3.2) months, 310 neuropsychiatric adverse events in the montelukast patients and 566 events in the LABA patients were identified. In the weighted cohort, the incidence rates of neuropsychiatric adverse events were 2.39 per 100 patient-years among the montelukast users and 2.41 per 100 patient-years among the LABA users. This translated to a weighted HR of 0.99 (95% CI, 0.84-1.16). No substantial differences were observed between the montelukast and LABA patients when analyzing the risk of specific neuropsychiatric adverse events: the HRs were 0.79 (95% CI, 0.54-1.14) for anxiety; 1.16 (95% CI, 0.70-1.95) for depression; 0.93 (95% CI, 0.76-1.13) for sleep-related disorders; 1.31 (95% CI, 0.64-2.69) for suicide and suicidal actions; 1.27 (95% CI, 0.84-1.90) for disrupted control of activity, attention, and behavior; and 0.51 (95% CI, 0.05-5.53) for confusion and psychotic-like symptoms. The risk of the primary outcome was consistent over subgroups and a range of sensitivity analyses.

Conclusions and Relevance: In this large study of children and adolescents based on data from routine clinical practice, there was no association between use of montelukast and the risk of neuropsychiatric adverse events. In aggregation with other robust observational studies, these results can inform the management of asthma and allergic rhinitis in this patient group.

Place, publisher, year, edition, pages
American Medical Association (AMA), 2025. Vol. 179, no 4, p. 418-427
National Category
Psychiatry
Identifiers
URN: urn:nbn:se:umu:diva-235716DOI: 10.1001/jamapediatrics.2024.5429ISI: 001405731500001PubMedID: 39836401Scopus ID: 2-s2.0-85217543683OAI: oai:DiVA.org:umu-235716DiVA, id: diva2:1939708
Funder
Swedish Asthma and Allergy Association, F2021-0019H.R.H. Crown Princess Lovisa's Association for Child Care, 2022-00740The Karolinska Institutet's Research Foundation, 2022-01608Consul Berghs Foundation, 220020Fredrik och Ingrid Thurings Stiftelse, 2022-00734Region Stockholm, 20200868Swedish Research Council, 2018-02640Swedish Research Council, 2023-02327Swedish Heart Lung Foundation, 20210416Available from: 2025-02-24 Created: 2025-02-24 Last updated: 2025-05-28Bibliographically approved

Open Access in DiVA

fulltext(452 kB)675 downloads
File information
File name FULLTEXT01.pdfFile size 452 kBChecksum SHA-512
da3182daddbd77987853ca37df84aa95a84242fd09c302f299240848b72b39908d5aa356a117a2a24814aad719949b607c2e2308acdbc20f6f5cac2c3d3e6d57
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Halldner, Linda

Search in DiVA

By author/editor
Halldner, Linda
By organisation
Child and Adolescent Psychiatry
In the same journal
JAMA pediatrics
Psychiatry

Search outside of DiVA

GoogleGoogle Scholar
Total: 677 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 355 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf